Adherence to oral diabetes medications among users and nonusers of antipsychotic medication

Psychiatric Services

Volumn 65, Issue 2, 2014, Pages 215-220

  Desai, Pooja R ^a   Adeyemi, Ayoade O ^a   Richards, Kristin M ^a   Lawson, Kenneth A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG USE; HUMAN; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; YOUNG ADULT; ADOLESCENT; COMPARATIVE STUDY; FEMALE; INSURANCE; MALE; MEDICARE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEXAS; UNITED STATES; YOUNG ADULT;

EID: 84893668406     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300118     Document Type: Article

References (38)

1. Correll CU, Druss BG, Lombardo I, et al: Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatric Services 61: 892-898, 2010
2. Hennekens CH, Hennekens AR, Hollar D, et al: Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150:1115-1121, 2005
3. Nasrallah HA, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006
4. Dixon L, Weiden P, Delahanty J, et al: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26:903-912, 2000
5. Mukherjee S, Decina P, Bocola V, et al: Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry 37: 68-73, 1996
6. Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495, 1989
7. Mai Q, Holman CD, Sanfilippo FM, et al: Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Medicine 9:118, 2011
8. Citrome L, Jaffe A, Levine J, et al: Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatric Services 57:1132-1139, 2006
9. National Diabetes Statistics, 2011. Bethesda, Md, National Institute of Health National Institute of Diabetes and Digestive and Kidney Diseases, 2011. Available at diabetes.niddk.nih.gov/dm/pubs/statistics/dm-statistics.pdf
10. Lau DT, Nau DP: Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27:2149-2153, 2004
11. Rozenfeld Y, Hunt JS, Plauschinat C, et al: Oral antidiabetic medication adherence and glycemic control in managed care. American Journal of Managed Care 14: 71-75, 2008
12. Ho PM, Rumsfeld JS, Masoudi FA, et al: Effect of medication non-adherence on hospitalization and mortality among patients with diabetes mellitus. Archives of Internal Medicine 166:1836-1841, 2006
13. Lawrence DB, Ragucci KR, Long LB, et al: Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin a1c goal attainment for HMO patients enrolled in a diabetes disease management program. Journal of Managed Care Pharmacy 12: 466-471, 2006
14. Krapek K, King K, Warren SS, et al: Medication adherence and associated hemoglobin a1c in type 2 diabetes. Annals of Pharmacotherapy 38:1357-1362, 2004
15. Pladevall M, Williams LK, Potts LA, et al: Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 27: 2800-2805, 2004
16. Sokol MC, McGuigan KA, Verbrugge RR, et al: Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care 43:521-530, 2005
17. Hepke KL, Martus MT, Share DA: Costs and utilization associated with pharmaceutical adherence in a diabetic population. American Journal of Managed Care 10:144-151, 2004
18. McCreadie RG, Scottish Schizophrenia Lifestyle Group: Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. British Journal of Psychiatry 183:534-539, 2003
19. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161: 692-699, 2004
20. Valenstein M, Blow FC, Copeland LA, et al: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 30:255-264, 2004
21. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630-639, 2002
22. Farley JF, Hansen RA, Yu-Isenberg KS, et al: Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. Primary Care Companion to CNS Disorders, 2012; doi 10.4088/PCC.11m0132414
23. Nelson LA, Graham MR, Lindsey CC, et al: Adherence to antihyperlipidemic medication and lipid control in diabetic Veterans Affairs patients with psychotic disorders. Psychosomatics 52:310-318, 2011
24. Dolder CR, Furtek K, Lacro JP, et al: Antihypertensive medication adherence and blood pressure control in patients with psychotic disorders compared to persons without psychiatric illness. Psychosomatics 46:135-141, 2005
25. Dolder CR, Lacro JP, Jeste DV: Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatic Medicine 65:156-162, 2003
26. Piette JD, Heisler M, Ganoczy D, et al: Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatric Services 58:207-212, 2007
27. Kreyenbuhl J, Dixon LB, McCarthy JF, et al: Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophrenia Bulletin 36:428-435, 2010
28. Coco-Perraillon M: Matching With Propensity Scores to Reduce Bias in Observational Studies. Burlington, Vt, Adheris, 2006. Available at www.nesug.org/proceedings/nesug06/an/da13.pdf
29. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. Journal of Clinical Epidemiology 45:197-203, 1992
30. Ramaswamy K, Masand PS, Nasrallah HA: Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Annals of Clinical Psychiatry 18:183-194, 2006
31. Goldberg RW, Kreyenbuhl JA, Medoff DR, et al: Quality of diabetes care among adults with serious mental illness. Psychiatric Services 58:536-543, 2007
32. Krein SL, Bingham CR, McCarthy JF, et al: Diabetes treatment among VA patients with comorbid serious mental illness. Psychiatric Services 57:1016-1021, 2006
33. Dixon LB, Kreyenbuhl JA, Dickerson FB, et al: A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatric Services 55:892-900, 2004
34. Desai MM, Rosenheck RA, Druss BG, et al: Mental disorders and quality of diabetes care in the Veterans Health Administration. American Journal of Psychiatry 159:1584-1590, 2002
35. Kreyenbuhl J, Leith J, Medoff DR, et al: A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Research 188:109-114, 2011
36. Himelhoch S, Brown CH, Walkup J, et al: HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS 23:1735-1742, 2009
37. Adeyemi AO, Rascati KL, Lawson KA, et al: Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis. Clinical Therapeutics 34:712-719, 2012
38. Dixon LB, Adler DA, Berlant JL, et al Psychiatrists and primary caring: what are our boundaries of responsibility? Psychiatric Services 58:600-602, 2007